top of page

Discussing the FIREFLY-1 pediatric low-grade glioma data with Day One Bio at #ASCO23

Day One Bio CEO Jeremy Bender describes tovorafenib FIREFLY-1 trial result and Day One’s Plan to seek an accelerated approval for the drug.



Comments


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page